check_circleStudy Completed

Contraception, Heavy menstrual bleeding

Bayer Identifier:

91392

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2004-002617-36

EU CT Number:

Not Available
Induction of CYP3A4 by rifampin

Trial purpose

Please see attached Study Results Summary below

Key Participants Requirements

Sex

N/A

Age

45 - 65 Years
  • -

  • -

Trial summary

Enrollment Goal
16
Trial Dates
March 2005 - May 2005
Phase
Phase 1
Could I Receive a placebo
N/A
Products
Natazia/Qlaira (EV/DNG, BAY86-5027)
Accepts Healthy Volunteer
N/A

Where to participate

StatusInstitutionLocation
Completed
Bayer Pharma AGBerlin, 13353, Germany

Trial design

One-arm, open-label, non-randomized study to evaluate the effect of rifampicin 600mg/ day, given over 5 days p.o., on the steady state pharmacokinetics of SH T00658M (2 mg estradiol valerate and 3 mg dienogest) in healthy postmenopausal volunteers
Trial Type
Interventional
Intervention Type
N/A
Trial Purpose
N/A
Allocation
N/A
Blinding
N/A
Assignment
N/A
Trial Arms
N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.